Last reviewed · How we verify
Primary cholangitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ocaliva | OBETICHOLIC ACID | Intercept Pharms Inc | Farnesoid X Receptor Agonist | Bile acid receptor | 2016-01-01 | |
| Ocaliva | Ocaliva | Universitaire Ziekenhuizen KU Leuven | G-protein coupled bile acid receptor 1, Bile acid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Intercept Pharms Inc · 1 drug in Primary cholangitis
- Universitaire Ziekenhuizen KU Leuven · 1 drug in Primary cholangitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Primary cholangitis:
- Primary cholangitis treatment updates — RSS
- Primary cholangitis treatment updates — Atom
- Primary cholangitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Primary cholangitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-cholangitis. Accessed 2026-06-10.
Related
- Primary cholangitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing